Deep Learning for Estimating Synaptic Health of Primary Neuronal Cell
  Culture by Kormilitzin, Andrey et al.
Deep Learning for Estimating Synaptic Health of
Primary Neuronal Cell Culture
Andrey Kormilitzin1,2,∗ Xinyu Yang1,2,∗ William H. Stone1,∗ Caroline Woffindale2,∗
Francesca Nicholls2 Elena Ribe2 Alejo Nevado-Holgado2 Noel Buckley2
1 Mathematical Institute, University of Oxford
2 Department of Psychiatry, University of Oxford
william.stone2@queens.ox.ac.uk
{andrey.kormilitzin, xinyu.yang, caroline.woffindale, francesca.nicholls,
elena.ribe, alejo.nevado-holgado, noel.buckley}@psych.ox.ac.uk
Abstract
Understanding the morphological changes of primary neuronal cells induced by
chemical compounds is essential for drug discovery. Using the data from a single
high-throughput imaging assay, a classification model for predicting the biological
activity of candidate compounds was introduced. The image recognition model
which is based on deep convolutional neural network (CNN) architecture with
residual connections achieved accuracy of 99.6% on a binary classification task of
distinguishing untreated and treated rodent primary neuronal cells with Amyloid-
β(25−35).
1 Introduction
Alzheimer’s disease is the third leading cause of death in the US and globally [1]. The economic
cost of Alzheimer’s disease is estimated to be $36.512 billion in the US alone and expected to rise
to $2 trillion by 2030 globally [2]. It has been shown that the β-Amyloid (Aβ) peptide is involved
in Alzheimer’s disease [3] and found in the brains of Alzheimer patients [4, 5]. Searching for new
chemical compounds, which moderate the previously identified Aβ driven DKK1-Wnt-PCP-JNK
neurotoxic signalling pathway, may reverse the effect of toxic depositions of Aβ plaques in the brain
and will inform the development of novel therapeutic approaches for the treatment of Alzheimer’s
disease. We hypothesise that by reversing or preventing these changes in gene expression, this may
protect against the toxic effects seen in primary rodent neuronal cultures following treatment with
Aβ(25−35). The standard and laborious approach to assess whether a candidate compound may have
a protective effect, is to perform a statistical hypothesis testing using the features extracted with
CellProflier image processing tool across various treatment regimes. The proposed deep-learning
approach eliminates the need for this statistical comparison and estimates the treatment effects from
raw pixels of high-throughput images.
2 Related work
Recent years have seen an explosion of applications of the deep learning methods to medical imaging,
including computer-aided diagnosis (CAD) in radiology and medical image analysis [6, 7, 8]. The
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efficiency of deep learning models for cytometry [9] has been widely recognised and applied to cell
imaging [10], virtual staining with generative adversarial networks (GAN) [11, 12], fluorescence
microscopy [13] and reconstructing cell cycles and disease progression [14]. However, despite the
wide popularity and maturity of the deep learning approach, very little has been done to estimate the
effect of biological activity of neuronal cells induced by compounds and searching for drugs that
may protect against neurodegeneration and Alzheimer’s disease. Simm et al. in [15] suggested to
re-purpose high-throughput images assay to predict biological activity in drug discovery, however
this approach depends on the features extracted from CellProfiler [16] and lacks the flexibility of the
CNN models [17] which learn features directly from raw pixels of images.
3 Materials and methods
3.1 The assay design
Primary neuronal cells were seeded in 96 well plates and cultured for 21 days in vitro to allow them
to establish neuronal connections and to synaptically mature. Cells are then pre-treated for one hour
with one candidate compound in doses of either 10, 3 or 1 µM2 before the addition of 30 µM of
Aβ(25−35) or a vehicle control. Cells are incubated for a further 48 hours before they are fixed and
stained for various markers. The assay plate configuration and the location of compounds and Aβ at
various doses (in µM) are presented in Fig. 1 and Tab. 1 respectively. For example, wells in column
’B’ at rows 2, 3, 4 and wells in columns ’C’ at rows 5,6,7 all contain zero dose of a compound and a
zero dose of Aβ, which corresponds to a vehicle control. Wells in column ’D’ and rows 2,3,4 and
wells in column ’E’ and rows 5,6,7 all contain a combination of 1 µM of a compound and 30 µM of
Aβ.
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Figure 1: An assay plate with wells.
Well position index Compound Aβ
B{2,3,4}, C{5,6,7} 0 0
C{2,3,4}, D{5,6,7} 0 30
D{2,3,4}, E{5,6,7} 1 0
E{2,3,4}, F{5,6,7} 1 30
F{2,3,4}, G{5,6,7} 3 0
G{2,3,4}, H{5,6,7} 3 30
H{2,3,4}, J{5,6,7} 10 0
F{2,3,4}, B{5,6,7} 10 30
Table 1: The position map of compounds and doses.
To highlight specific cellular structure, four stains were used: MAP2 (neuronal cytoskeleton marker),
PSD-95 (post-synaptic protein marker), Synaptophysin (pre-synaptic protein marker) and Hoescht
33342 (nucleic marker). Cells are then imaged at magnification of 40x using the high-content GE
IN Cell Analyzer 6000TM imaging system. Each well was images 30 times (’field views’) using
non-overlapping strides for each of the four channels; MAP2 (Cy5), Nucleus (DAPI), Synaptophysin
(dsRed), PSD-95 (FITC). This resulted in 5760 images per plate used in the analysis.
3.2 The deep learning model
The objective of this work was to develop a classification model able to reliably recognise
morphological changes in neuronal cells treated with Aβ(25−35) versus the vehicle control
(’untreated’). Once trained to a satisfactory accuracy, the the model was applied to screen candidate
compounds and determine whether images of cells treated with a compound + Aβ(25−35) were more
similar to those treated with Aβ(25−35) alone. For this purpose, we developed a CNN-based [17]
binary classifier. The model used in classification is based on the Resnet18 [18] architecture with
weights pre-trained on the ImageNet data [19] and implemented in PyTorch [20] and fastai [21]
python libraries. The model was fine-tuned on a binary classification task using 6480 of untreated
and 6480 of treated images of neuronal cells of size 2048 by 2048 pixels. To mitigate the problem of
overfitting, data augmentations with default settings of random cropping, flipping both horizontally
and vertically, small rotations and shearing were used. We used dropout [22] of 0.35, leading to
stable convergence. The training was done using SGD with momentum of 0.9, slanted learning rate
2µM stands for micro molar, is a measure of the concentration of a chemical substance in a solution
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[23, 24] with the optimal one [25]. The batch size of 4 was used due to memory limitation of NVIDIA
2080Ti GPU. The entire training procedure was split into two bits: first training the classification
head and then gradual unfreezing of convolutional layers. The classification head comprised one fully
connected layers of 512 neurons with ReLU activation function [26] and the final binary softmax
function. No weight decay was used.
In order to visualise individual pixels that supported the decision of the classification model and for
sanity check that the model’s decisions are not due to image artefacts the weighted Grad-CAM [27]
was implemented. The visualisation methods showed that the “attention” of the model was drawn
towards specific neurites; providing assurance that the model fit true features of the data.
Aβ peptide has been found as a dominant mediator of neuronal dystrophy and synaptic loss [28]
which is reflected in the morphology of neuronal cytoskeleton structure. Therefore in the current
work we focused only the Cy5 stain which highlights the cytoskeleton structure. However, we are
planning on extending this approach and develop a multi-channel model which learns from all four
stains simultaneously. We believe that further inclusion of all four channels (Cy5, DAPI, dsRed
and FITC) will improve the detection capability and improve our understanding of morphological
changes induced by compounds at various doses.
4 Results
Of 36 assay plates, with a unique compound in each plate, 34 were randomly selected for training
and the remaining 2 for testing. However, the model was trained only on images of neurons treated
with vehicle controls and Aβ, whereas all remaining wells with various treatment regimes were
unused. Therefore the unused images can be safely used for inference. The main reason behind
setting aside two assay plates was to test the model performance on vehicle controls and Aβ. The
list of 36 compounds is presented in Table 5 in A. and the distribution of predicted scored of vehicle
controls and Aβ are presented in Fig. 4 and Fig. 5.
We applied data augmentation to training images including random scaling, flipping, cropping, and
other affine transformations using the package imgaug [29]. The model was trained for 10 epochs
on the last convolution block and the fully connected layer with learning rate 1e-3, and another 10
epochs on all layers with learning rate 1e-4, all using the stochastic gradient descent (SGD) optimizer
with momentum 0.9. The training results are summarised in Table 2.
Training loss Training accuracy Validation loss Validation accuracy
0.012 99.68% 0.013 99.58%
Table 2: Training and validation accuracies and losses.
In the inference mode, the model prediction scores for each individual well were averaged over field
views. The resulting prediction for each treatment regimen was averaged over six wells and the
standard deviation computed. The results of model predictions for Raubasine and Thiamphenicol
compounds are presented in Tables 3 and 4 respectively. The threshold of 0.5 was used to convert
predicted scores to dichotomous categories (untreated and treated with 30 µM of Aβ(25−35)).
compound dose (µM) 0 0 1 1 3 3 10 10
Aβ dose (µM) 0 30 0 30 0 30 0 30
well1 0.0 0.87 0.01 0.92 0.01 0.93 0.01 0.69
well2 0.01 0.93 0.0 0.83 0.07 0.86 0.07 0.68
well3 0.21 0.87 0.04 0.7 0.47 0.94 0.01 0.87
well4 0.08 0.91 0.0 0.82 0.07 0.96 0.02 0.81
well5 0.03 0.93 0.06 0.87 0.01 0.84 0.03 0.91
well6 0.0 0.89 0.0 0.48 0.02 0.68 0.04 0.71
mean predicted score 0.05 0.9 0.02 0.77 0.10 0.87 0.03 0.78
standard deviation 0.11 0.21 0.07 0.27 0.14 0.18 0.09 0.29
Table 3: An example of screening of Raubasine compound at various doses.
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The combination of zero dose of both a compound and Aβ corresponds to a vehicle control. For
example, the neuronal cells treated with Raubasine 1 µM and 30 µM of Aβ, were classified as
treated with Aβ 30 µM , which means there is a not significant protective effect of Raubasine at
this dose against synaptic loss induced by Aβ. Similarly, neuronal cells treated with larger doses of
Raubasine (10 µM ) were also classified as treated with only Aβ.
compound dose (µM) 0 0 1 1 3 3 10 10
Aβ dose (µM) 0 30 0 30 0 30 0 30
well1 0.01 0.83 0.02 0.95 0.01 0.78 0.05 0.87
well2 0.02 0.83 0.01 0.96 0.01 0.76 0.03 0.79
well3 0.03 0.93 0.08 0.9 0.04 0.86 0.02 0.68
well4 0.0 0.84 0.18 0.76 0.01 0.81 0.01 0.85
well5 0.0 0.86 0.0 0.81 0.01 0.85 0.01 0.94
well6 0.0 0.88 0.01 0.85 0.06 0.97 0.02 0.98
mean predicted score 0.01 0.86 0.05 0.87 0.02 0.84 0.02 0.85
standard deviation 0.03 0.22 0.07 0.19 0.07 0.23 0.06 0.2
Table 4: An example of screening of Thiamphenicol compound at various doses.
5 Conclusions
We report the validation accuracy of 99.58% on a binary images classification problem using high-
throughput images of neuronal cells that have been treated with vehicle control versus images treated
with 30 µM of Aβ(25−35). Amyloid-β is thought to induce synapse loss. The developed deep
learning based high throughput method which is able to identify and measure this synapse loss and
then use this technique to identify when compounds can rescue it.
None of 36 screened compounds (Table 5) applied to neuronal cells at various doses was found as
having a substantial protective effect against Aβ(25− 35). This result was confirmed by screening
the same assay plates of 36 compounds using the image processing pipeline of CellProfiler followed
by statistical hypothesis testing of the extracted features.
In contrast to a deep CNN model, CellProfiler [16] requires a substantial amount of computational
resource to process the same number of images. For example, with 48 CPUs, a typical imaging
processing of a single plate takes approximately 15 hours to complete in contrast to 60 seconds
using the deep learning model in the inference mode. In addition to a long computation time, large
scale screening of hundreds or thousands of compounds will result in a substantial carbon footprint
compared to re-suing of pre-trained deep learning models.
The visualisation of pixel-wise attention of the model using Grad-CAM is presented in B. The results
demonstrated in Fig. 2 and Fig. 3 are randomly selected images from each of the treatment regimes
for two compounds (Raubasine and Thiamphenicol) which were not used in the training (hold-out
set). Various bits of the cytoskeleton structure found important for the classification decision of the
model. The Grad-CAM methods highlights the important regions in the image for predicting the
class label.
The predicted scores are predominantly distributed around zero or one, except for a few wells (C).
This chart allows neurobiologists to manually inspect particular wells where the distribution of
predicted scores is not clustered around zero or one. Such cases might be caused by contaminated
wells, blurred imaging or other artefacts which may confuse the image classification model.
Learning synaptic features and segmentation of cytoskeleton structure have been explored previously
[30, 31, 32]. Recently, a signature-based approach [33, 34] to learning from ordered data has been
proposed and applied to various tasks in image and character recognition [35, 36, 37]. The signature
transforms sequentially ordered data - a path, into a succinct representation, effectively capturing
global and local information. The signature transformation is used as feature representation in
downstream machine learning tasks. The signature method was used in mental health [38, 39, 40],
prediction of diagnosis of Alzheimer’s disease [41, 42], finance [43, 44, 45] and deep signature
learning [46]. The cytoskeleton structure could be factorised into a collection of branching diagrams,
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making it suitable for signature-based learning. We plan to investigate this approach to effective
learning of morphological changes of neuronal cells in our future works.
Although the images of neuronal cells were taken from rodents, potentially the developed method
could be generalised in humans via transfer learning with the final goal of efficiently identifying novel
compounds to reverse the effect of Aβ and drug development for neurodegeneration and Alzheimer’s
disease.
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A List of compounds used for training and screening
Amprolium Bucladesine Camptothecin Carbimazol Cefapirin
Chloropyrazine Chloroquine Chrysenequinone Cyclopentolate Danazol
Diflunisal Dihydroergotamine Doxylamine Ellipticine Ethisterone
Etidronic Acid Fulvestrant Harpagoside Irinotecan Isocarboxazid
Levobunolol Menadione Mephenytoin Mercaptopurine Metaclopramide
Ofloxacin Orciprenaline Oxolamine Oxybenzone Piperlongumine
Puromycin Raubasine Rifabutin Sanguinarine Terazosin
Thiamphenicol
Table 5: A list of candidate compounds used for training and screening.
B Grad-CAM visualisation
The model predictions using images of two randomly selected compounds: Raubasine and
Thiamphenicol are presented in Fig. 2 and Fig. 3. The pooled scores of these two compounds
over an assay plate are summarised in Tables 3 and 4 respectively.
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(a) (1, 0, 0.991) (b) (1, 30, 0.998)
(c) (3, 0, 0.996) (d) (3, 30, 0.999)
(e) (10, 0, 0.995) (f) (10, 30, 0.999)
Figure 2: Random images from the plate with Raubasine compound. Each image is described by a
triple (a, b, c), where a - compound dose (µM ), b - Aβ(25−30) dose (µM ) and the predicted score
from the model that the image was classified correctly. Left column corresponds to treatments with
only Raubasine at various regimes and without added 30 µM of Aβ(25−30).
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(a) (1, 0, 0.999) (b) (1, 30, 0.999)
(c) (3, 0, 0.918) (d) (3, 30, 0.999)
(e) (10, 0, 0.998) (f) (10, 30, 0.997)
Figure 3: Random images from the plate with Thiamphenicol compound. Each image is described
by a triple (a, b, c), where a - compound dose (µM ), b - Aβ(25−30) dose (µM ) and the predicted
score from the model that the image was classified correctly. Left column corresponds to treatments
with only Thiamphenicol at various regimes and without added 30 µM of Aβ(25−30).
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C Distribution of predicted scores within wells
Plots below demonstrate the distribution of predicted scores for each images from within the same
well using the two held-out assay plates with Raubasine and Thiamphenicol compounds. Each
row corresponds to a single compound treatment and six columns denote replications of the same
treatment, following the assay plate structure as shown in Fig. 1.
Figure 4: A distribution of the predicted scores for Raubasine.
10
Figure 5: A distribution of the predicted scores for Thiamphenicol. Each column corresponds to a
single compound configuration. Six columns correspond to.
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